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Purpose: To assess the value of extending the routinely used base-of-skull (BOS) to
upper-thigh field of view (FOV) to include the head on 18F-FDG PET/CT in cancer patients.
Methods:We retrospectively reviewed 1000 consecutive top-of-head to foot PET/CT stud-
ies. Abnormalities above BOS were categorized as unsuspected or known and were
correlated with pathology, MRI/CT, and clinical follow-up.
Results: Of the 1000 patients, 102 (10.2%) had potentially significant findings above BOS.
Of these, 70/102 (69%) were known and 32/102 (31%) were unsuspected. Of the patients
with unsuspected findings, follow-up data was unavailable in 7/32 (22%) and abnormalities
were confirmed in 25/32 (78%). Of the 25 confirmed unsuspected findings, 4/25 (16%)
were false positives and 21/25 (84%) were true positives. Of these, 13/21 (62%) were con-
firmed metastatic, and 8/21 (38%) were benign. Unsuspected finding of brain metastasis
changed the management in 11/13 (85%) and staging in 4/13 (31%).
Conclusion: Including the head in PET/CT FOV incidentally detected clinically significant
findings in 2.1% (21/1000) of patients.The detection of previously unsuspected metastasis
had significant impact on patient management and provided more accurate staging.
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INTRODUCTION
Positron emission tomography (PET) using fluorine-18-2-deoxy-
d-glucose (18F-FDG) diagnoses, stages, and restages many cancers
with an accuracy ranging from 80 to 90% (Czernin and Phelps,
2002).
In oncology, Whole Body (WB) PET/CT (positron emission
tomography – computed tomography) is typically performed from
the base-of-skull (BOS) to the pelvic-floor (Von Schulthess et al.,
2006). The use of the term WB is misleading since the most com-
monly used field of view (FOV) does not include the brain/skull,
and significant portions of upper and lower extremities. Even in
melanoma patients, in whom top-of-head to the feet is the stan-
dard of care, routine inclusion of the head and extremities has
been recently questioned (Niederkohr et al., 2007).
Brain metastasis is a common complication of cancer affect-
ing 15–40% of patients (Grupta et al., 1999). These patients have
a poor prognosis even in the absence of systemic disease, with a
median survival time ranging from 9 to 18 months (Chidel et al.,
1999). The most common primary cancers that metastasize to the
brain in adults are lung (40%), breast, colon, renal cell carcinoma,
and melanoma. In children, the most common are sarcoma and
germ cell tumor. The cerebral cortex is the most common location
for cerebral metastasis (80%) with multiple lesions in two-thirds
of the patients (Vecht, 1998).
Our objective was to evaluate the incremental added value of
extending the routinely used PET/CT FOV, BOS to upper-thigh,
to include the head in imaging different cancer patients.
MATERIALS AND METHODS
PATIENTS
We retrospectively evaluated all available data for a total of 1000
consecutive patients referred for clinical evaluation of known or
suspected malignancy and who had undergone top-of-head to
bottom of feet PET/CT scans, the standard of care at our institu-
tion. The primary diagnosis was: lung (n= 314), head and neck
(n= 228), gastrointestinal (n= 181), lymphoma (n= 113), breast
(n= 39), and others (n= 125). Patients who were referred for
melanoma staging or metastatic brain lesions of unknown pri-
mary were excluded from the study since the brain is typically
included in these cases.
PET/CT SCANNING
An intravenous 5.18 MBq/kg (0.14 mCi/kg) injection of 18F-FDG
was administered after the patient had fasted at least 4 h. Patients
sat in a quiet room without talking during the subsequent 60 min
of the FDG uptake phase. Blood glucose level was <200 mg/dl
in all patients. All scans were acquired using a PET/CT scanner
(Gemini TF; Philips Medical Systems) with an axial co-scan range
of 193 cm.
CT SCANNING
The CT component of the PET/CT scanner consisted of a 64 slice
multidetector helical CT with a gantry port of 70 cm. Parameters
were as follows for 20–21 bed acquisitions: 120–140 kV and 33–
100 mAs (based on body mass index), 0.5 s per CT rotation, pitch
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of 0.9 and 512× 512 matrix. CT data were used for image fusion
and the generation of the CT transmission map. In all patients,
the arms were placed above the patient’s head for CT acquisition
except in patients with head and neck cancers where the arms were
placed at the patient’s sides. The CT images were obtained without
oral or IV contrast.
PET SCANNING AND IMAGE PROCESSING
The PET component of the PET/CT scanner is composed
of Lutetium-Yttrium Oxyorthosilicate (LYSO)-based crystals.
Emission data were acquired on average for 20–21 bed posi-
tions (193 cm coverage, identical to the CT protocol). Emis-
sion scans were acquired at 1–2 min per bed position. The
FOV was from the top-of-head to the bottom of feet in all
patients. The three-dimentional (3D) WB acquisition parame-
ters consisted of a 128× 128 matrix and an 18 cm FOV with
a 50% overlap. Processing consisted of the 3D Row Action
Maximum Likelihood Algorithm (RAMLA) method (Browne
and De Pierro, 1996). Total scan time per patient was 20–
45 min.
IMAGE ANALYSIS
PET/CT images were retrospectively evaluated on Extended Bril-
liance workstation (Philips Medical Systems) by two board-
certified Nuclear Medicine physicians. A log was kept to record
cases of suspected lesions above the BOS. Final interpretation was
reached by consensus. Data were categorized into two groups:
known pathology and new, previously unidentified pathology
above the BOS. Suspected pathology was correlated with surgical
pathology, MRI and/or CT, or clinical follow-up. The impact on
management and/or staging from the detection of unidentified
pathology above the BOS was confirmed by a board-certified
oncologist.
RESULTS
Of the 1000 PET/CT cases, 102 (10.2%) patients had clinically sig-
nificant PET/CT findings above the BOS. Of these, 70/102 (69%)
patients were known or suspected to have pathology above the
BOS based on clinical and radiographic data. Those were excluded
from our final analysis. The remaining 32/102 patients (31%) had
new unsuspected findings above the BOS. Follow-up data was
not available for 7/32 (22%) patients. Abnormal findings were
confirmed in the remaining 25/32 (78%) patients. Of these 25
patients, 4/25 (16%) were false positive and 21/25 (84%) were
true positive. Metastasis was confirmed in 13/21 (62%; 12 male
and 1 female, mean ages 62). Patient characteristics and the dis-
tribution of malignant lesions above the BOS are summarized in
Table 1. The remaining 8/21 (38%) patients had confirmed benign
pathology (Figure 1) above the BOS (four males and four females,
mean ages 69). Patient characteristics are summarized in Table 2.
Of significance, 2/13 patients (15%) with unsuspected metas-
tases had their only malignant site in the brain; both with treated
lung cancer (Figure 2). One patient had a left frontoparietal
lobe lesion as the only metastatic site on initial staging PET/CT
(Figure 3). Unsuspected finding of brain metastasis changed the
management in 11/13 (85%) patients and upstaged 4/13 (31%)
patients (Table 1).
Positron emission tomography was false positive in 4/25
patients, two with focal sellar uptake, one with increased uptake in
bilateral lentiform nuclei and thalamus, and one with focal right
frontal lobe uptake (Figure 4). All of these patients had a normal
follow-up brain MRI.
Table 1 | Patients with unsuspected finding of malignant lesions above the base-of-skull.
No. Primary G Age Distribution of
brain lesions
Stage with
LWB
Stage with
TWB
Change in management
1 Neuroendocrine of the
cecum
M 44 Rt (right) frontoparietal IV IV Unknown
2 Lung M 67 Lt (left) temporal IV IV whole brain (WB) radiation
3 Lung M 65 Rt frontal I IV surgical resection followed by WB
radiation
4 Lung F 80 Rt frontal and Lt
temporoparietal
I IV Cyberknife therapy
5 Lung M 65 Multiple III IV WB radiation
6 Lung M 65 Lt frontal IV IV WB radiation
7 Lung M 61 Rt frontal IV IV Cyberknife therapy
8 Right nasal cavity M 27 Rt parietal and Lt frontal IV IV WB radiation
9 Lung M 64 Rt frontal IV IV WB radiation
10 Lung M 63 Rt temporal IV IV Cyberknife therapy
11 Mucoepidermoid tumor
of right tongue
M 66 Lt frontal IV IV Unknown
12 Lung M 63 Rt frontal and parietal IV IV WB radiation
13 Lung M 70 Lt frontoparietal I IV WB radiation
LWB, limited whole body field of view from the base of the skull to the upper-thighs.
TWB, true whole body field of view from the top of the skull to the feet.
Frontiers in Oncology | Cancer Imaging and Diagnosis April 2013 | Volume 3 | Article 71 | 2
Abdelmalik et al. Added value of head in PET/CT
FIGURE 1 | Sixty-five-year-old female with a history of thyroid
and metastatic breast cancers as well as schwannoma which
was surgically resected. On restaging PET/CT: MIP, transaxial
PET, CT, and fused images (A) demonstrated an unsuspected
finding of recurrent schwannoma in addition to metastatic breast
cancer. PET/CT finding was confirmed on MRI (B). The patient
subsequently underwent surgical resection of the recurrent
shwannoma.
Table 2 | Patients with unsuspected finding of benign lesions above the base-of-skull.
Patient no. Primary Gender Age Benign finding Change in management
1 Lung M 63 Lipoma Unknown
2 Lung F 83 Infarction No change
3 Lung M 59 Pituitary macroadenoma No change
4 Gastric F 71 Pituitary macroadenoma No change
5 Lung M 79 Benign atrophy No change
6 Thyroid/breast F 65 Recurrent schwannoma Resection of recurrent tumor
7 Abdominal liposarcoma M 74 Infarction Started on Aspirin
8 Squamous cell carcinoma of head and neck F 61 Neurosarcoid Unknown
DISCUSSION
PET/CT technology has been in rapid evolution and dissemina-
tion. It is becoming a standard procedure in the management of
many cancer patients. However, the FOV for WB-PET/CT imag-
ing of cancer patients is not standardized and varies between
institutions (Huston et al., 2010). The most commonly used WB-
PET/CT FOV protocols only images from the BOS to the upper-
thighs. A publication from the National Oncologic PET Registry
(NOPR) showed that the FOV for PET was not recorded in 8.4%
of PET/CT reports (Coleman et al., 2010). Furthermore, there
has been significant variation among sites in individual descrip-
tions of craniocaudal anatomic landmarks within this FOV. Beyer
et al. (2011) reported that the term BOS was used to describe
supraclavicular anatomic landmark in 53% of sites.
The routinely used FOV may underestimate the true extent
of the disease by missing metastases to areas outside the typical
BOS to upper-thigh FOV. Initial studies are beginning to appear
in the literature documenting the added value of top-of-head to
feet FDG PET imaging in some types of cancers (Nguyen et al.,
2007). In a recent publication by NOPR evaluating the impact
of dedicated brain PET on intended patient management, they
concluded that dedicated brain PET was associated with simi-
lar net changes in intended management as in the overall NOPR
cohort (Hillner et al., 2011). In a previous study, 4% of cancer
patients who underwent top-of-head to feet PET/CT, had unde-
tected malignant sites outside the typical BOS to upper-thigh FOV
(Osman et al., 2010). The co-scan range for combined CT and
PET imaging is approximately 145 cm for most of the different
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FIGURE 2 | Eighty-year-old female with non-small-cell lung cancer in the
right lung status post Cyberknife therapy. On restaging PET/CT: MIP
(maximum intensity projection) and transaxial PET, CT, and fused images (A)
demonstrated complete response to therapy in the right lung and a new left
temporoparietal lobe lesion suspicious for metastasis. PET/CT finding was
confirmed on MRI (B). Adding the brain to the imaged field of view changed
both staging (I–IV) and management as patient underwent whole brain
radiation.
FIGURE 3 | Seventy-year-old male with bronchogenic carcinoma in
the right lung. On initial staging PET/CT: MIP, transaxial PET, CT, and
fused images (A) demonstrated a single lesion in the right lung and
unsuspected photopenia in the left frontoparietal lobe that corresponds to
a hypodensity on CT suspicious for metastasis. PET/CT finding was
confirmed on MRI (B). Adding the brain to the imaged field of view
changed both staging (I–IV) and management as patient underwent whole
brain radiation.
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FIGURE 4 | Seventy-one-year-old male with metastatic squamous
cell carcinoma of the head and neck. On follow-up PET/CT: MIP,
transaxial PET, CT, and fused images (A) demonstrated an unsuspected
hypermetabolic focus is the right frontal lobe with no definite
abnormality on CT in addition to metastatic head and neck cancer. Brain
MRI was negative for metastasis (B). In this case PET was falsely
positive and the focal uptake in the right frontal lobe was thought to be
due to artifact.
PET/CT scanner designs offered by the major vendors of med-
ical imaging equipment (Townsend et al., 2004). Therefore, for
most PET facilities, top-of-head to feet PET/CT imaging would
require two separate image acquisitions with patient reposition-
ing in between. However, including the head in the FOV would
require only single image acquisition in all available PET/CT
scanners.
In a similar previous study performed in 1026 patients, uniden-
tified abnormal brain findings were detected in 1.1% (0.4% were
malignant and 0.7% were benign) (Ludwig et al., 2002). In another
older study performed with 273 patients, unidentified cerebral
metastasis were only detected in 0.7% of patients (Larcos and
Maisey, 1996). Both studies evaluated PET only images and there-
fore lacking the anatomic information provided by the CT portion
of PET/CT. Furthermore, the impact of the unsuspected detection
of brain lesions was not fully assessed in either study.
In our study, the presence of previously unidentified pathology
above the BOS was confirmed in 2.1% of 1000 patients. Of those,
malignant findings were confirmed in 1.3% (13/1000) and benign
findings were confirmed in 0.8% (8/1000). A change in patient
management was seen in 85% (11/13) of patients with new detec-
tion of malignancy above the BOS and upstaging in 31% (4/13).
Also, the presence of previously unknown benign findings above
the BOS resulted in change of patient management two of the
eight patients (25%). We propose to extend the commonly used
BOS to upper-thigh FOV to include the head as the standard of
care in imaging cancer patients.
The sensitivity of PET is suboptimal in detecting brain metas-
tases due to the intense physiologic background uptake in the brain
and the hypometabolic nature of some brain metastases. There-
fore, contrast-enhanced MRI has been reported to have higher
sensitivity and specificity for brain metastases than PET (Rohren
et al., 2003). Although guidelines from the National Comprehen-
sive Cancer Network (NCCN) included brain MRI as part of
the initial work-up of non-small-cell lung cancer, it has not yet
been enforced (National Comprehensive Cancer Network, 2011).
The decision to obtain a brain MRI is left to the oncologist and
may only be recommended for symptomatic patients or patients
with advanced disease. Furthermore, NCCN guidelines did not
recommend brain MRI for restaging or surveillance of these
patients unless they become symptomatic. In our study, 50% of
patients with primary lung cancer and unsuspected brain metasta-
sis had their unsuspected brain findings on restaging/surveillance
PET/CT scans. In addition, two patients had brain lesions as the
only abnormalities on PET/CT (Figure 1).
In our study, patients with lung cancer represented 67% of the
patients with unsuspected pathology above the BOS. However,
we cannot conclude with confidence that lung cancer is the only
malignancy that would benefit most from including the head in
the FOV. Such a conclusion would be fraught with potential pit-
falls if the incidence and prevalence of various cancers are not
taken into account. Also, selection bias represents an additional
limitation since PET/CT scans are not routinely obtained in breast
cancer patients at our institution.
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Extending the BOS to upper-thigh FOV in PET/CT to
include the head will only increase the scan time by 1–
5 min. Furthermore, although the FDG dose would be the
same, including the head will minimally increase the patient’s
radiation dose in the low-dose non-contrast CT portion. Of
importance, the Medicare reimbursement rates for top-of-
head to foot and BOS to upper-thigh have equal technical
fees ($1037.34) with a difference of $2.89 in professional fees
($127.74 vs. $124.8). Therefore, including the head in the imaged
FOV in PET/CT would not represent any significant financial
burden.
Our study is not without limitations. The prevalence of patient
motion resulting from the increased scan time was not evaluated.
In addition, the CT component of the PET/CT was done using
lower-dose technique and without contrast. We are also unable to
provide an estimate of the false negative rate of top-of-head to
foot PET/CT FOV in this retrospective study. Furthermore, the
impact of false positive results and related costs and anxiety was
not addressed. Lastly, a dedicated brain PET-CT acquisition was
not performed on these patients. However, our goal was not to
assess specificity or sensitivity of extending the BOS to upper-
thigh FOV to include the head, but rather document its potential
added value.
CONCLUSION
We propose that including the head in the PET/CT imaged FOV
may offer additional benefit to cancer patients by detecting clin-
ically significant findings. Detection of additional metastasis in
these patients had significant impact on patient management and
provided more accurate staging.
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